Chapter 473 Thrombotic Disorders in Children
Epidemiology
The majority of children who develop a TE have multiple risk factors that may be acquired, inherited, and/or anatomic (Table 473-1). The presence of a central venous catheter (CVC) is the single most important risk factor for venous thromboembolism (VTE) in pediatric patients, associated with approximately 90% of neonatal VTE and 60% of childhood VTE. These catheters are often necessary for the care of premature neonates and children with acute and chronic diseases and are used for intravenous hyperalimentation, chemotherapy, dialysis, antibiotics, or supportive therapy. CVCs may damage the endothelial lining and/or cause blood flow disruption, increasing the risk of thrombosis. There are multiple other acquired risk factors that are associated with thrombosis, including trauma, infection, chronic medical illnesses, and medications. Cancer, congenital heart disease, and prematurity are the most common medical conditions associated with TEs.
Table 473-1 POTENTIAL PROTHROMBOTIC STATES
CONGENITAL
Deficiency of anticoagulants
AT-III, protein C or protein S, plasminogen
Resistance to cofactor proteolysis
Factor V Leiden
High levels of procoagulants
Prothrombin 20210 mutation
Elevated factor VIII levels
Damage to endothelium
Homocystinemia
ACQUIRED
Obstruction to flow
Indwelling lines
Pregnancy
Polycythemia/dehydration
Immobilization
Injury
Trauma, surgery, exercise
Inflammation
IBD, vasculitis, infection, Behçet syndrome
Hypercoagulability
Pregnancy
Malignancy
Antiphospholipid syndrome
Nephrotic syndrome
Oral contraceptives
L-Asparaginase
Elevated factor VIII levels
RARE OTHER ENTITIES
Congenital
Dysfibrinogenemia
Acquired
Paroxysmal nocturnal hemoglobinuria
Thrombocythemia
Vascular grafts
AT-III, antithrombin III; IBD, inflammatory bowel disease.
Antiphospholipid antibody syndrome (APS) is a well-described syndrome in adults characterized by recurrent fetal loss and/or thrombosis. Antiphospholipid antibodies (APA) are associated with both venous and arterial thrombosis. The mechanism by which these antibodies cause thrombosis is not well understood. A diagnosis of APS requires the presence of both clinical and laboratory abnormalities (see under Laboratory Testing). The laboratory abnormalities must be persistent for 12 wk. Because of the high risk of recurrence, patients with APS often require long-term anticoagulation. It is important to note that healthy children may have a transient lupus anticoagulant, often diagnosed because of a prolonged PTT on routine preoperative testing. These antibodies may be associated with a recent viral infection and are not a risk factor for thrombosis.
Clinical Manifestations
Pulmonary embolism (PE): Symptoms of PE include shortness of breath, pleuritic chest pain, cough, hemoptysis, fever, and, in the case of massive PE, hypotension and right heart failure. Based on autopsy studies, PEs are often not diagnosed, perhaps because young children are unable to accurately describe their symptoms and their respiratory deterioration may be masked by other conditions (Chapter 401.1).